Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%. Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%. Revises outlook for Adjusted EBITDA for 2024. Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets. Announces record six new contract agreements in the qua ...

The upcoming report from Evolent Health (EVH) is expected to reveal quarterly earnings of $0.30 per share, indicating no change from the year-ago quarter compared to the year-ago period. Analysts forecast revenues of $625.58 million, representing an increase of 22.4% year over year.Over the last 30 days, there has been a downward revision of 2.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial fore ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Evolent Health (EVH) . This company, which is in the Zacks Internet - Software industry, shows potential for another earnings beat.This health care software and consulting services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the la ...

The market expects Evolent Health (EVH) to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected ...

Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to ...

Investment Thesis - Evolent Health (EVH) is rumored to be taken private with a bid valuing the company at approximately $3.8 billion [2] - The current bid implies a valuation of 21x forward free cash flow to enterprise value, suggesting a potential 15% upside to the stock price at $32 per share [2] - The company may still be undervalued, and further bids could emerge in the coming days [2] Evolent's Business Model - Evolent Health provides healthcare services and technology solutions aimed at improving care quality and reducing costs for patients with complex conditions [3] - The company partners with health plans to manage care in expensive treatment areas like oncology and cardiology [3] - Evolent uses data-driven strategies and advanced payment models to optimize healthcare costs, creating value for customers such as insurance companies [3] Revenue Growth and Earnings - Evolent's revenue growth rates are expected to decelerate substantially in the second half of 2024 [4] - The company has a history of modest earnings surprises, with recent surprises ranging from -1.52% to 6.80% [6] - Despite a slight improvement in revenue growth rates in early 2024, the market has been skeptical of Evolent's prospects prior to acquisition rumors [6] Valuation and Financial Outlook - Evolent could be acquired for $3.8 billion, with Elevance Health (ELV) being a potential bidder [8] - The company is targeting $220 million in free cash flow by the end of 2024 and a $300 million exit run rate by year-end [8][10] - Evolent's enterprise value is estimated at $4.5 billion, factoring in $200 million in preferred shares, $600 million in debt, and $100 million in cash and marketable securities [11] - A higher bid of $4.3 billion for equity could push the enterprise value to $5 billion, representing a 23x forward free cash flow multiple [11] Market Reaction and Stock Performance - Prior to acquisition rumors, Evolent's stock was down approximately 15% year-to-date [12] - The stock saw a decline from earlier highs despite Q2 2024 earnings results, but acquisition rumors have sparked renewed investor interest [7] - If acquisition talks fall through, the stock could drop, but the company remains undervalued at 18x to 20x forward free cash flow [14] Potential Upside - A takeover bid could drive Evolent's shares up by an additional 15% in the coming weeks [14] - The combination of a solid business model and the possibility of a lucrative buyout makes Evolent a compelling investment opportunity [14]

For the quarter ended June 2024, Evolent Health (EVH) reported revenue of $647.15 million, up 37.9% over the same period last year. EPS came in at $0.30, compared to $0.14 in the year-ago quarter. The reported revenue represents a surprise of +2.04% over the Zacks Consensus Estimate of $634.18 million. With the consensus EPS estimate being $0.21, the EPS surprise was +42.86%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Evolent Health, Inc. (NYSE:EVH) Q2 2024 Results Conference Call August 8, 2024 5:00 PM ET Company Participants Seth Frank - Vice President of Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Anne Samuel - JPMorgan Jeff Garro - Stephens Charles Rhyee - TD Cowen Kevin Caliendo - UBS Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Stephanie Davis - SVB ...

Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 42.86%. A quarter ago, it was expected that this health care software and consulting services provider would post earnings of $0.21 per share when it actually produced earnings of $0.34, delivering a surprise of 61. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVH New York Stock Exchange (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d ...